Low-Dose Aspirin and Progression of Age-Related Hearing Loss
Authors: Clark David P. Q. , Zhou Zhen , Hussain Sultana M. , Tran Cammie , Britt Carlene , Storey Elsdon , Lowthian Judy A. , Shah Raj C. , Dillon Harvey , Wolfe Rory , Woods Robyn L. , Rance Gary , McNeil John J. 
Published: July 2024

ImportanceAge-related hearing loss is common in an aging population, affecting communication and contributing to a worsened quality of life. It occurs as a result of cochlear degeneration and may be further exacerbated by inflammation and microvascular changes, as observed in animal models.ObjectiveTo compare the effect of daily low-dose aspirin vs placebo on the progression of age-related hearing loss in healthy older adults.Design, Setting, and ParticipantsA prespecified secondary analysis was conducted of the Aspirin in Reducing Events in the Elderly (ASPREE) randomized clinical trial. Participants were 279 healthy community-dwelling individuals living in Australia who were aged 70 years or older and free of overt cardiovascular diseases, dementia, and life-limiting illnesses. Participants were recruited between January 1, 2010, and December 31, 2014, and followed up over 3 years. Statistical analysis was completed from June to December 2023.InterventionA 100-mg daily dose of enteric-coated aspirin or matching placebo.Main Outcomes and MeasuresHearing measures were air conduction audiometry and binaural speech perception in noise. Assessments were conducted at baseline, 18 months, and 3 years. The change from baseline hearing measures were analyzed using an intention to treat approach. Aspirin and placebo were compared using mixed linear regression models adjusting for age, sex, diabetes, and smoking.ResultsOf 279 participants, 154 (55%) were male, and the median age at baseline was 73.1 years (IQR, 71.5-76.2 years). A total of 98 of 138 participants (71%) in the aspirin group and 94 of 141 participants (67%) in the placebo group reported experiencing hearing loss at baseline. Compared with placebo, aspirin did not affect the changes in mean (SD) 4-frequency average hearing threshold from baseline to year 3 (aspirin: baseline, 27.8 [13.3] dB; year 3, 30.7 [13.7] dB; difference, 3.3 [3.9] dB; placebo: baseline, 27.5 [12.6] dB; year 3, 30.9 [13.8] dB; difference, 3.0 [4.8] dB; P = .55) nor any other tested frequencies. An increase in air conduction threshold indicates a deterioration in hearing. Similarly, for the mean (SD) speech reception threshold, there was no significant difference observed between the aspirin and placebo group at the year 3 follow-up assessment (aspirin: baseline, –9.9 [3.8] dB; year 3, –9.1 [3.8] dB; difference, 0.9 [2.9] dB; placebo: baseline, –10.5 [7.1] dB; year 3, –9.6 [4.1] dB; difference, 0.9 [5.9] dB; P = .86). The findings were consistent across sex, age groups, diabetic and smoking status.Conclusions and RelevanceIn this secondary analysis of the ASPREE randomized clinical trial, low-dose aspirin did not affect the progression of age-related hearing loss. More investigation is warranted on whether a longer follow-up or the use of a more powerful anti-inflammatory agent might prove beneficial.Trial Registrationanzctr.org.au Identifier: ACTRN12614000496617